The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity.
Novo Nordisk's Wegovy and Eli Lilly's Mounjaro have demonstrated remarkable commercial success, with Wegovy sales reaching 9.6 billion DKK in Q3 2023, driving significant share price increases for both companies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.